

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application. Please amend the claims as follows:

Claims 1-54 (cancelled)

55. **(Currently Amended)** An isolated recombinant polypeptide comprising (a) the amino acid sequence of SEQ ID NO:2 or,
~~(b) an immunogenic fragment of at least 57 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject as a conjugate with a suitable carrier or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.~~

56. **(Canceled)**

57. **(Previously Presented)** The isolated recombinant polypeptide of claim 55, wherein the polypeptide consists of the amino acid sequence SEQ ID NO:2.

58. **(Currently Amended)** ~~The isolated recombinant polypeptide of claim 55, wherein the polypeptide comprises~~ An isolated recombinant polypeptide comprising an immunogenic fragment of at least ~~57~~ 40 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered either alone or coupled to a co-protein carrier ~~to a subject as a conjugate with a suitable carrier or in a composition which can include an adjuvant~~, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

59. **(Previously Presented)** An isolated recombinant fusion protein comprising the isolated recombinant polypeptide of claim 55.

60. **(Canceled)**

61. **(Currently Amended)** ~~The~~ An isolated recombinant fusion protein comprising the isolated recombinant polypeptide of claim ~~[[55]]~~ 58, ~~wherein the polypeptide comprises an immunogenic fragment of at least 57 contiguous amino acids of SEQ ID NO:2, wherein the~~

~~immunogenic fragment, when administered to a subject as a conjugate with a suitable carrier or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.~~

62. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 55, and a pharmaceutically acceptable carrier.

63. (Previously Presented) An immunogenic composition comprising the isolated recombinant fusion protein of claim 59, and a pharmaceutically acceptable carrier.

64-67. (Canceled)

68. (Previously Presented) A method for inducing an antibody in a mammal comprising administering the isolated recombinant polypeptide of claim 55 to the mammal in an amount effective to induce an antibody.

69. (Canceled)

70. (Canceled)

71. (Canceled)

72. (Canceled)

73. (Previously Presented) The immunogenic composition of claim 62, further comprising at least one other *Moraxella catarrhalis* antigen other than a polypeptide comprising SEQ ID NO:2.

74. (Previously Presented) The immunogenic composition of claim 63, further comprising at least one other *Moraxella catarrhalis* antigen other than a polypeptide comprising SEQ ID NO:2.

75. **(New)** An immunogenic composition comprising the isolated recombinant polypeptide of claim 58 and a pharmaceutically acceptable carrier.
76. **(New)** An immunogenic composition comprising the isolated recombinant fusion protein of claim 61 and a pharmaceutically acceptable carrier.
77. **(New)** The immunogenic composition of claim 62, further comprising an adjuvant.
78. **(New)** The immunogenic composition of claim 63, further comprising an adjuvant.
79. **(New)** The immunogenic composition of claim 75, further comprising an adjuvant.
80. **(New)** The immunogenic composition of claim 76, further comprising an adjuvant.
81. **(New)** The isolated recombinant polypeptide of claim 58, wherein the polypeptide is coupled to a carrier.
82. **(New)** The isolated recombinant polypeptide of claim 58, wherein the immunogenic fragment consists of at least 40 contiguous amino acids of SEQ ID NO:2.
83. **(New)** The isolated recombinant fusion of claim 61, wherein the immunogenic fragment consists of at least 40 contiguous amino acids of SEQ ID NO:2.
84. **(New)** The immunogenic composition of claim 75, wherein the immunogenic fragment consists of at least 40 contiguous amino acids of SEQ ID NO:2.